Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 35HER2-positive Breast Cancer 3Brain Neoplasms 3Neoplasm Metastasis 2Endometrial Neoplasms 2Breast Diseases 2Anatomic Stage II Breast Cancer AJCC v8 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Solid Tumors 1Solid Cancer 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Motor Activity 1Metastatic Breast Cancer With a Isolated Brain Progression 1Meningeal Neoplasms 1Meningeal Carcinomatosis 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma 1Lung Neoplasms 1Invasive Breast Cancer 1Inflammatory Breast Neoplasms 1Hematologic Neoplasms 1

Interventions

palbociclib 3Anastrozole 3pertuzumab 2Trastuzumab 2Gonadotropin-Releasing Hormone 2AZD9833 2trastuzumab deruxtecan 1taxane 1ribociclib 1abemaciclib 1Letrozole 1Genotype 1Fulvestrant 1Denosumab 1Body Height 1Blood Pressure 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Breast Diseases × pertuzumab × Clear all
NCT04784715 2026-05-22

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

AstraZeneca

Phase 3 Active not recruiting
1,157 enrolled 1 FDA
Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT03304080 2025-07-18

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

Icahn School of Medicine at Mount Sinai

Phase 1/2 Active not recruiting
44 enrolled
Breast

Breast Diseases, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡